Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).

Zhang Y, Saavedra E, Tang R, Gu Y, Lappin P, Trajkovic D, Liu SH, Smeal T, Fantin V, De Botton S, Legrand O, Delhommeau F, Pernasetti F, Louache F.

Sci Rep. 2017 Aug 4;7(1):7305. doi: 10.1038/s41598-017-07848-8.

2.

Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility.

Martinez R, Blasina A, Hallin JF, Hu W, Rymer I, Fan J, Hoffman RL, Murphy S, Marx M, Yanochko G, Trajkovic D, Dinh D, Timofeevski S, Zhu Z, Sun P, Lappin PB, Murray BW.

PLoS One. 2015 Sep 23;10(9):e0138616. doi: 10.1371/journal.pone.0138616. eCollection 2015.

3.

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, Tang RW, Wang H, Tsaparikos K, Wang J, Timofeevski S, Katayama R, Dinh DM, Lam H, Lam JL, Yamazaki S, Hu W, Patel B, Bezwada D, Frias RL, Lifshits E, Mahmood S, Gainor JF, Affolter T, Lappin PB, Gukasyan H, Lee N, Deng S, Jain RK, Johnson TW, Shaw AT, Fantin VR, Smeal T.

Cancer Cell. 2015 Jul 13;28(1):70-81. doi: 10.1016/j.ccell.2015.05.010. Epub 2015 Jul 2.

4.

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

Zou HY, Li Q, Engstrom LD, West M, Appleman V, Wong KA, McTigue M, Deng YL, Liu W, Brooun A, Timofeevski S, McDonnell SR, Jiang P, Falk MD, Lappin PB, Affolter T, Nichols T, Hu W, Lam J, Johnson TW, Smeal T, Charest A, Fantin VR.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3493-8. doi: 10.1073/pnas.1420785112. Epub 2015 Mar 2.

5.

Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition.

Liu CN, Mathialagan N, Lappin P, Fortner J, Somps C, Seitis G, Johnson TR, Hu W, Matsumoto D.

Toxicol Sci. 2015 Jan;143(1):116-25. doi: 10.1093/toxsci/kfu213. Epub 2014 Oct 16.

PMID:
25326243
6.

Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib.

Zhang CC, Yan Z, Giddabasappa A, Lappin PB, Painter CL, Zhang Q, Li G, Goodman J, Simmons B, Pascual B, Lee J, Levkoff T, Nichols T, Xie Z.

Cancer Med. 2014 Jun;3(3):462-71. doi: 10.1002/cam4.215. Epub 2014 Feb 27.

7.

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer.

Cirone P, Andresen CJ, Eswaraka JR, Lappin PB, Bagi CM.

Cancer Chemother Pharmacol. 2014 Mar;73(3):525-38. doi: 10.1007/s00280-014-2376-1. Epub 2014 Jan 19.

PMID:
24442130
8.

Contrast agents for quantitative microCT of lung tumors in mice.

Lalwani K, Giddabasappa A, Li D, Olson P, Simmons B, Shojaei F, Van Arsdale T, Christensen J, Jackson-Fisher A, Wong A, Lappin PB, Eswaraka J.

Comp Med. 2013;63(6):482-90.

9.

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.

Fang DD, Zhang CC, Gu Y, Jani JP, Cao J, Tsaparikos K, Yuan J, Thiel M, Jackson-Fisher A, Zong Q, Lappin PB, Hayashi T, Schwab RB, Wong A, John-Baptiste A, Bagrodia S, Los G, Bender S, Christensen J, Vanarsdale T.

PLoS One. 2013 Jun 27;8(6):e67258. doi: 10.1371/journal.pone.0067258. Print 2013.

10.

Expression of proto-oncogene cFMS protein in lung, breast, and ovarian cancers.

Kakiuchi-Kiyota S, Lappin PB, Heintz C, Brown PW, Pinho FO, Ryan AM, Mathialagan N.

Appl Immunohistochem Mol Morphol. 2014 Mar;22(3):188-99. doi: 10.1097/PAI.0b013e31828e7104.

PMID:
23702648
11.

Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.

Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, Zong Q, Lappin PB, Wong A, Rejto PA, Smeal T, Christensen JG.

Clin Cancer Res. 2012 Sep 15;18(18):5008-19. doi: 10.1158/1078-0432.CCR-12-1379. Epub 2012 Jul 17.

12.

Vaccination with cancer- and HIV infection-associated endogenous retrotransposable elements is safe and immunogenic.

Sacha JB, Kim IJ, Chen L, Ullah JH, Goodwin DA, Simmons HA, Schenkman DI, von Pelchrzim F, Gifford RJ, Nimityongskul FA, Newman LP, Wildeboer S, Lappin PB, Hammond D, Castrovinci P, Piaskowski SM, Reed JS, Beheler KA, Tharmanathan T, Zhang N, Muscat-King S, Rieger M, Fernandes C, Rumpel K, Gardner JP 2nd, Gebhard DH, Janies J, Shoieb A, Pierce BG, Trajkovic D, Rakasz E, Rong S, McCluskie M, Christy C, Merson JR, Jones RB, Nixon DF, Ostrowski MA, Loudon PT, Pruimboom-Brees IM, Sheppard NC.

J Immunol. 2012 Aug 1;189(3):1467-79. doi: 10.4049/jimmunol.1200079. Epub 2012 Jun 27.

13.

Renal uptake and tolerability of a 2'-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey.

Henry SP, Johnson M, Zanardi TA, Fey R, Auyeung D, Lappin PB, Levin AA.

Toxicology. 2012 Nov 15;301(1-3):13-20. doi: 10.1016/j.tox.2012.06.005. Epub 2012 Jun 16.

PMID:
22709826
14.

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.

Simmons BH, Lee JH, Lalwani K, Giddabasappa A, Snider BA, Wong A, Lappin PB, Eswaraka J, Kan JL, Christensen JG, Shojaei F.

Cancer Chemother Pharmacol. 2012 Aug;70(2):213-20. doi: 10.1007/s00280-012-1899-6. Epub 2012 Jun 9.

PMID:
22684718
15.

Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer.

Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, Simmons BH, Wu A, Lee JH, Bergqvist S, Kraynov E.

J Exp Clin Cancer Res. 2012 Mar 23;31:26. doi: 10.1186/1756-9966-31-26.

16.

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.

Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG.

Cancer Lett. 2012 Jul 1;320(1):48-55. doi: 10.1016/j.canlet.2012.01.026. Epub 2012 Jan 21.

PMID:
22269210
17.

[(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells.

Zhang CC, Yan Z, Li W, Kuszpit K, Painter CL, Zhang Q, Lappin PB, Nichols T, Lira ME, Affolter T, Fahey NR, Cullinane C, Spilker M, Zasadny K, O'Brien P, Buckman D, Wong A, Christensen JG.

Clin Cancer Res. 2012 Mar 1;18(5):1303-12. doi: 10.1158/1078-0432.CCR-11-1433. Epub 2011 Dec 14.

18.

Urethral bulking with polymethylmethacrylate microspheres for stress urinary incontinence: tissue persistence and safety studies in miniswine.

Lemperle G, Lappin PB, Stone C, Lemperle SM.

Urology. 2011 Apr;77(4):1005.e1-7. doi: 10.1016/j.urology.2010.12.021. Epub 2011 Feb 18.

PMID:
21333337
19.

Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.

Hu-Lowe DD, Chen E, Zhang L, Watson KD, Mancuso P, Lappin P, Wickman G, Chen JH, Wang J, Jiang X, Amundson K, Simon R, Erbersdobler A, Bergqvist S, Feng Z, Swanson TA, Simmons BH, Lippincott J, Casperson GF, Levin WJ, Stampino CG, Shalinsky DR, Ferrara KW, Fiedler W, Bertolini F.

Cancer Res. 2011 Feb 15;71(4):1362-73. doi: 10.1158/0008-5472.CAN-10-1451. Epub 2011 Jan 6.

20.

Flow cytometry in preclinical drug development.

Lappin PB.

Methods Mol Biol. 2010;598:303-21. doi: 10.1007/978-1-60761-401-2_21.

PMID:
19967522
21.
22.

Ovarian choriocarcinoma in a rhesus monkey associated with elevated serum chorionic gonadotropin levels.

Farman CA, Benirschke K, Horner M, Lappin P.

Vet Pathol. 2005 Mar;42(2):226-9.

PMID:
15753479
23.

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.

Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, Lappin PB, Riccobene T, Abramian D, Sekut L, Sturm B, Poortman C, Minter RR, Dobson CL, Williams E, Carmen S, Smith R, Roschke V, Hilbert DM, Vaughan TJ, Albert VR.

Arthritis Rheum. 2003 Nov;48(11):3253-65.

25.

The response of pulmonary vascular endothelial cells to monocrotaline pyrrole: cell proliferation and DNA synthesis in vitro and in vivo.

Lappin PB, Ross KL, King LE, Fraker PJ, Roth RA.

Toxicol Appl Pharmacol. 1998 May;150(1):37-48.

PMID:
9630451
27.

Vitamin A or zymosan pretreatment attenuates alpha-naphthylisothiocyanate-induced liver injury.

Bailie MB, Jean PA, Lappin PB, Scozzaro MJ, Schmidt TM, Moulin FJ, Roth RA.

Toxicol Appl Pharmacol. 1995 Sep;134(1):63-70.

PMID:
7676458
28.

Platelets and alpha-naphthylisothiocyanate-induced liver injury.

Bailie MB, Pearson JM, Lappin PB, Killam AL, Roth RA.

Toxicol Appl Pharmacol. 1994 Dec;129(2):207-13.

PMID:
7992311
29.

Disseminated trichosporonosis in a neutropenic murine model.

Hospenthal D, Belay T, Lappin P, Rogers A, Kennedy M.

Mycopathologia. 1993 May;122(2):115-22.

PMID:
8327000
30.

Difficult dermatologic diagnosis.

Lappin PB, Dunstan RW.

J Am Vet Med Assoc. 1992 Mar 15;200(6):785-6. No abstract available.

PMID:
1568923
31.

Evaluation of retinal thresholds for C.W. laser radiation.

Dunsky IL, Lappin PW.

Vision Res. 1971 Jul;11(7):733-8. No abstract available.

PMID:
4998440
32.

Assessment of ocular damage thresholds for laser radiation.

Lappin PW.

Am J Optom Arch Am Acad Optom. 1971 Jul;48(7):600-6. No abstract available.

PMID:
4998086
33.

Relative sensitivity of various areas of the retina to laser radiation.

Lappin PW, Coogan PS.

Arch Ophthalmol. 1970 Sep;84(3):350-4. No abstract available.

PMID:
4989738
34.

Histologic evaluation of ophthalmoscopically subvisible retinal laser exposures.

Lappin PW, Coogan PS.

Invest Ophthalmol. 1970 Jul;9(7):537-42. No abstract available.

PMID:
4987524
35.

Ocular damage thresholds for the helium-neon laser.

Lappin PW.

Arch Environ Health. 1970 Feb;20(2):177-83. No abstract available.

PMID:
4983491
36.

Retinal irradiances from the He-Ne CW laser.

Lappin PW.

Am J Optom Arch Am Acad Optom. 1968 May;45(5):279-91. No abstract available.

PMID:
4971454
37.

Congenital hemolytic anemia associated with spherocytosis; report of four cases.

LAPPIN PJ.

R I Med J. 1956 Feb;39(2):79-80; passim. No abstract available.

PMID:
13298483

Supplemental Content

Loading ...
Support Center